Schizophrenia: Reversal Of Atypical Antipsychotic Drug-induced Obesity And Its Related Metabolic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$619,854.00
Summary
Atypical antipsychotic drugs such as olanzapine are commonly used to treat mental illnesses such as schizophrenia. While these drugs are effective, their side effects of obesity and metabolic disorders are a major hurdle leading to a serious lack of compliance in taking medication. This project aims to develop better antipsychotic treatment with reduced side-effects including obesity and metabolic disorders for mental illness patients.